GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc

In a report released on September 21, Trung Huynh from RBC Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,975.00. T...

RBC Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Goldsky Resources ( ($TSE:GSKR) ) has shared an update. Goldsky Resources has launched a 25,000‑meter diamond drilling program at its 100%‑owned Ba...

Goldsky Resources Begins Major Drill Program at Sweden’s Barsele Gold Project

Goldsky Resources ( ($TSE:GSKR) ) has shared an update. Goldsky Resources plans to issue 1,166,130 common shares to Haywood Securities as partial p...

Goldsky Resources to Pay Advisory Fee with Shares After Securing Full Control of Barsele

In a report released yesterday, Matthew Weston from UBS maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at p1,90...

UBS Remains a Hold on GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The Phase 2 study A Phase 2, Parallel Group, Randomized, Double-Blind, ...

GSK Halts Key Phase 2 Alzheimer’s Trial, Resetting Investor Expectations

In a report released yesterday, from Berenberg Bank upgraded GlaxoSmithKline to a Buy, with a price target of $60.00. Currently, the analyst consen...

Positive Report for GlaxoSmithKline (GSK) from Berenberg Bank

Citi analyst Graham Parry maintained a Hold rating on GlaxoSmithKline today and set a price target of £21.00. According to TipRanks, Parry is ranke...

GlaxoSmithKline (GSK) Receives a Hold from Citi

In a report released yesterday, Trung Huynh from RBC Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,975.00. Huynh c...

GlaxoSmithKline (GSK) Gets a Hold from RBC Capital

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK plc has disclosed a series of small share acquisitions by several senior exe...

GSK Executives Acquire Shares Under Company Reward Plan

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK disclosed that Maya Martinez-Davis, the company’s President, US, has acquired notiona...

GSK Reports Executive Acquisition of Notional ADS in Savings Plan

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has granted a conditional share award to Chief People Officer and Executiv...

GSK Grants Performance-Based Share Award to Chief People Officer

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has disclosed awards of ordinary shares to two senior figures under its 2025 Share Va...

GSK awards share-based incentives to senior leadership under 2025 plan

GlaxoSmithKline ( ($GSK) ) has shared an update. In its second-quarter 2026 results, announced on 28 July 2026, GSK reported sales of £8.4 billion,...

GSK Boosts Q2 2026 Sales and Launches £1.9bn Accelerate Growth Programme to Fund Late-Stage R&D

HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.


HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is running a new early stage trial called “A Phas...

GSK Advances Early-Stage Lung Drug With New Formulation Study

Goldsky Resources ( ($TSE:GSKR) ) has provided an update. Goldsky Resources has appointed Carl Danielsson as Manager of Communications and Public A...

Goldsky Strengthens Nordic Stakeholder Strategy with Senior Communications Hire

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a phase 3 study called “A Study of Depemokim...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$49.80	+0.17%	1.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$49.80	+0.2%	1.35M
3
4
5
6

GSK

Get GSK plc Data in Excel

Get GSK plc Data in Excel